Australian medical equipment company Anteris (AVR.US) IPO priced at $6.78 per share, aiming to raise $100 million.
The company plans to issue 14.8 million shares of stock at a price of $6.78 per share to raise $100 million in funds.
Australian artificial heart valve manufacturer Anteris Technologies announced its IPO terms on Monday. The company plans to issue 14.8 million shares at a price of $6.78 per share to raise $100 million. At the proposed price, Anteris Technologies will have a market value of $244 million.
The company's stock is currently listed on the Australian Securities Exchange under the code "AVR". The $6.78 pricing is based on its closing price on the ASX on December 5.
Anteris is a structural heart company focused on patients with aortic stenosis. Its flagship product, DurAVR transcatheter heart valve (THV) system, consists of a single piece bioprosthetic valve. To date, a total of 73 patients in the United States, Canada, and Europe have received treatment with the DurAVR THV system.
The company was founded in 1999 and had revenue of $3 million in the 12 months ending September 30, 2024. The company plans to list on Nasdaq under the stock code "AVR". Anteris submitted its application in secrecy on February 14, 2024. TD Cowen, Barclays, and Cantor Fitzgerald are the joint book-runners for this transaction.
Related Articles
HK Stock Market Move | EVEREST MED(01952) up more than 3%, Liripoz approved by FDA, expected to submit BLA in the first half of next year in Greater China region.
Morgan Stanley: Update CSPC PHARMA (01093) risk-return assessment, target price lowered to 10.4 Hong Kong dollars.
HK Stock Market Move | CMOC Group Limited (03993) rose nearly 4% in the afternoon, planning to spend $1 billion to acquire a gold mining project in Brazil. The annual gold production is expected to increase by about 8 tons.
HK Stock Market Move | EVEREST MED(01952) up more than 3%, Liripoz approved by FDA, expected to submit BLA in the first half of next year in Greater China region.
Morgan Stanley: Update CSPC PHARMA (01093) risk-return assessment, target price lowered to 10.4 Hong Kong dollars.
HK Stock Market Move | CMOC Group Limited (03993) rose nearly 4% in the afternoon, planning to spend $1 billion to acquire a gold mining project in Brazil. The annual gold production is expected to increase by about 8 tons.
RECOMMEND
Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025
What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025
Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025
